Table 1.
Clinical characteristics of patients administered bosutinib
| Characteristics | Frequency | P value | |
|---|---|---|---|
| Standard dose | Dose escalation | ||
| Total number | 10 | 15 | |
| Female: male | 5:5 | 8:7 | |
| Age (year) | 63.0 (34.0–78.0) | 55.0 (19.0–81.0) | 0.183 |
| Phase, CP: AP: BP | 7:2:1 | 15:0:0 | |
| Reason of taking bosutinib, TKI-R: TKI-Int: de novo CML | 4:5:1 | 9:6:0 | |
| Body weight (kg) | 59.9 (40.8–69.1) | 53.0 (44.1–86.3) | 0.889 |
| Laboratory test values | |||
| White blood cell (*103/mm3) | 8.5 (3.6–190.7) | 6.1 (1.3–13.8) | 0.332 |
| Hemoglobin (g/dL) | 10.3 (8.2–14.2) | 12.1 (8.3–14.8) | 0.052 |
| Platelet (*104/mm3) | 29.5 (12.1–326.0) | 19.4 (12.8–162.0) | 0.120 |
| Aspartate transaminase (IU/L) | 23.0 (14.0–56.0) | 24.0 (10.0–47.0) | 0.487 |
| Alanine transaminase (IU/L) | 17.5 (9.0–65.0) | 23.0 (7.0–34.0) | 0.232 |
| Serum albumin (g/dL) | 4.1 (3.7–4.3) | 4.2 (3.0–5.2) | 0.179 |
| Total bilirubin (mg/dL) | 0.6 (0.2–0.9) | 0.6 (0.3–2.7) | 0.557 |
| Serum creatinine (mg/dL) | 0.8 (0.5–0.9) | 0.7 (0.4–1.7) | 0.803 |
| Lipase (IU/L) | 21.5 (5.0–75.0) | 18.0 (6.0–38.0) | 0.781 |
Data presented as number or median (minimum–maximum)
TKI tyrosine kinase inhibitor, R resistance, Int intolerance